secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0000950170-24-073072
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics annual meeting: all 9 directors elected, auditor ratified, say-on-pay approved
--------------------------------------------------------------------------------

- All nine director nominees elected with 89.8M-90.8M votes for and 1.5M-2.4M withheld.
- Ratification of WithumSmithBrown as auditor passed: 128.6M for, 2.4M against.
- Advisory say-on-pay approved: 87.8M for, 3.7M against, 0.7M abstentions.
- Board amended bylaws effective June 11, 2024, updating advance notice and California code compliance.
- Bylaw changes include Rule 14a-19 compliance requirement and electronic meeting provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017024073072/0000950170-24-073072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017024073072/lctx-20240613.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-073072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer